A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Status:
Withdrawn
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies the side effects of stereotactic body radiation therapy and
pazopanib hydrochloride in treating patients with kidney cancer who are not able to undergo
surgery. Stereotactic body radiation therapy is a specialized radiation therapy that delivers
high doses of radiation directly to the tumor and may kill more tumor cells and cause less
damage to normal tissue. Pazopanib hydrochloride may stop the growth of tumor cells by
blocking an enzyme needed for cell growth. Giving pazopanib hydrochloride before stereotactic
body radiation therapy may help make the tumor smaller and be an alternative treatment for
patients who cannot undergo surgery.